Solara Active Pharma Q4 FY26: Date, Estimates 2026

Key event investors are tracking

Solara Active Pharma Sciences (NSE: SOLARA) is expected to announce its Q4 FY26 financial results for the quarter and full year ended March 31, 2026, in May 2026. The company has indicated that its board of directors is scheduled to meet in May 2026 (expected) to approve the audited financial statements. The same meeting is also expected to consider a recommendation for a final dividend for FY26. For investors, the Q4 print matters because recent quarters have shown a gap between revenue momentum and profitability. The stock has also been volatile across the year, making the next audited numbers an important reference point for positioning.

Board meeting and expected Q4 FY26 results date

The company has scheduled its Q4 FY26 results for May 2026 (expected). As outlined in the update, the board will meet to approve the audited consolidated financial statements for the quarter and full year ended March 31, 2026. This is also the point where any recommendation on a final dividend for FY26 may be considered. Separately, the company has closed the trading window for designated employees until 48 hours after the results announcement, in line with SEBI regulations. The trading-window closure is a standard compliance step, but it also signals that the company is nearing a price-sensitive disclosure.

Shareholding pattern: promoter holding steady at 42%

In the latest shareholding pattern update, promoter holding remained unchanged at 42.00% in the March 2026 quarter. While this disclosure does not indicate fresh buying or selling by promoters, it provides continuity at a time when investors are watching earnings and business mix. A stable promoter stake can be relevant for institutional and retail investors assessing alignment and long-term intent. The update does not provide changes for other categories in the excerpt, so the key data point remains the unchanged 42% promoter holding.

What brokerages are pencilling in for Q4

Brokerages including MOFSL, YES Securities, JM Financial, and others have published Q4 FY26 preview estimates for Solara Active Pharma Sciences. The consensus range cited expects Q4 FY26 revenue of ₹265 to ₹288 crore. Profit after tax (PAT) is estimated at ₹13 to ₹18 crore. Margin expectations are projected at 5.5% to 7%. These estimates are framed against the company’s Q3 FY26 performance reference in the same coverage, where revenue is cited at ₹248 crore in one comparison line, while the detailed quarterly table and other disclosures cite total income/revenue at ₹349 crore for Q3 FY26.

Stock price setup going into results

Solara Active Pharma Sciences was cited as trading at a current market price of ₹480 (as of April 2026) in the preview. The same data points place the stock’s 52-week high at ₹780 and 52-week low at ₹360. Another data snippet in the provided context mentions a 52-week high of ₹734.20 and a low of ₹441.10, and also notes the stock closing at ₹471.20 on February 9, 2026, down 10.10% on the day. These differing 52-week ranges appear to come from different snapshots and dates, but together they underline the volatility around earnings and profitability commentary.

Recap of Q3 FY26: revenue up, losses continued

For Q3 FY26, Solara Active Pharma Sciences reported revenue/total income of ₹349 crore, alongside a consolidated net loss of ₹17.43 crore. In the same set of disclosures, Q3 FY25 total income is shown at ₹301.80 crore and net profit at ₹8.09 crore, highlighting a year-on-year swing into losses. EBITDA for Q3 FY26 is cited at ₹37.40 crore, with EBITDA margin at 10.70% versus 19.60% in Q3 FY25. The quarter also included an exceptional item loss of ₹6.75 crore. Net profit margin for the quarter is shown at -4.99%, with basic EPS at -₹3.98.

Business mix: Growth API strength vs ibuprofen pressure

Management commentary around Q3 FY26 repeatedly pointed to a split in performance between the Growth API segment and the Base Ibuprofen business. The Growth API segment was described as operating at around 25% EBITDA margin, with gross margins north of 55%. At the consolidated level, gross margin for the quarter was described at about 47%, down by around 386 basis points sequentially, attributed primarily to headwinds in the ibuprofen-based business. The company also indicated it is evaluating strategic options for the ibuprofen business, reflecting continued pressure from excess capacities, newer technologies, and lower realizations.

Balance sheet actions: rights issue and debt reduction

The company’s rights issue program was cited as having raised ₹311.85 crore out of a total ₹449.95 crore as of December 31, 2025. Gross debt decreased to ₹630 crore from ₹776 crore, a 19% reduction. Management commentary also cited debt reduction of about ₹146 crore (adjusted for foreign exchange impact), with ₹113 crore linked to rights issue proceeds and ₹33 crore from operational cash flows. Another balance-sheet snapshot in the provided text noted cash and cash equivalents at ₹3.87 crore, described as the lowest level in recent history in that context.

Market impact: why this Q4 print is a key datapoint

The Q4 FY26 outcome will be read against three visible markers in the recent data. First, investors have seen revenue scale to ₹349 crore in Q3 FY26, but profitability remained negative at a net loss of ₹17.43 crore. Second, Street estimates for Q4 FY26 imply lower revenue than Q3’s ₹349 crore level, at ₹265-288 crore, while projecting positive PAT of ₹13-18 crore and margins of 5.5-7%. Third, the stock’s trading level around ₹480 versus a cited 52-week high of ₹780 and low of ₹360 frames how sensitive valuations could be to audited results and any dividend recommendation.

Key numbers at a glance

Broader earnings calendar context

The preview also referenced that TCS declared Q4 FY26 results on April 9, 2026. While TCS is not comparable operationally to an API manufacturer like Solara, the mention signals the market’s broader transition into Q4 FY26 earnings season. For Solara, audited numbers and any dividend recommendation are likely to dominate investor focus, alongside commentary on the ibuprofen business review.

Conclusion

Solara Active Pharma Sciences’ Q4 FY26 results, expected in May 2026, come at a time when promoter holding has stayed constant at 42% and the stock is trading well below its cited 52-week high. Brokerages are expecting revenue of ₹265-288 crore and PAT of ₹13-18 crore, with margins of 5.5-7%. Investors are likely to compare the audited Q4 outcome and any final dividend recommendation against Q3 FY26’s ₹349 crore revenue and -₹17.43 crore net loss. The next formal step is the board meeting in May 2026 (expected), after which the trading window will reopen 48 hours post announcement as per the stated compliance process.